Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406829 | 1.00 | SLC2A1 (0.42) | SLC2A1IDO1TDO2AOC3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2034769 | 0.98 | SLC2A1 (0.45) | SLC2A1IDO1TDO2AOC3ALDH1A1 | |
| SCHEMBL23222166 | 0.89 | SLC2A1 (0.48) | SLC2A1AOC3ALDH1A1SLC6A4 | |
| SCHEMBL1728650 | 0.88 | SLC2A1 (0.51) | SLC2A1IDO1TDO2AOC3SLC6A4 | |
| SCHEMBL1729608 | 0.88 | SLC2A1 (0.51) | SLC2A1IDO1TDO2AOC3SLC6A4 | |
| SCHEMBL5448531 | 0.88 | SLC2A1 (0.51) | SLC2A1IDO1TDO2AOC3SLC6A4 | |
| SCHEMBL22129792 | 0.86 | SLC2A1 (0.58) | SLC2A1IDO1TDO2AOC3SLC6A4 | |
| SCHEMBL11076863 | 0.82 | DPP4 (0.44) | IDO1TDO2AOC3DPP4MAOA | |
| SCHEMBL1728781 | 0.82 | SLC6A4 (0.57) | IDO1TDO2AOC3SLC6A4DPP4 | |
| SCHEMBL1364755 | 0.82 | SLC6A4 (0.57) | IDO1TDO2AOC3SLC6A4DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937064-B2 | Pyrazolo[1,5-a]pyrimidines useful as JAK2 inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-20 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-8420679-B2 | Aminothiazole derivatives and their use as CRF receptor ligands | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| US-20110118255-A1 | PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JAK2 INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-19 | — | — | US | disclosed |
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | SANOFI-AVENTIS (FR) | 2007-12-06 | — | — | US | disclosed |
| EP-1200419-B1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI SYNTHELABO (FR) | 2004-04-14 | — | — | EP | disclosed |
| US-6586456-B1 | Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide | SANOFI-SYNTHELABO (FR) | 2003-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | CRH, CRHR1, CRHR2 | SLC2A1 3178/4885IDO1 3043/4885TDO2 2241/4885 |
| US-20110118255-A1 | PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JAK2 INHIBITORS | JAK2, JAK1, JAK3 | SLC2A1 4376/4885IDO1 435/4885TDO2 1606/4885 |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | SLC2A1 4854/4885IDO1 449/4885TDO2 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.